高剂量与低剂量糖皮质激素治疗社区获得性肺炎的网络荟萃分析
该系统评价与网络荟萃分析纳入截至2026年1月25日的32项随机对照试验、共9746例社区获得性肺炎(CAP)住院患者,比较糖皮质激素高剂量(地塞米松等效剂量≥7.5 mg/d)与低剂量(<7.5 mg/d)方案。与安慰剂或常规治疗相比,高剂量与低剂量的短期全因死亡率均较低,但两种剂量之间未见明确的死亡率差异,该间接比较的置信度低。
要点
- 与安慰剂或常规治疗相比,高剂量与低剂量激素均与较低的短期死亡率相关。
- 高剂量与低剂量激素的间接比较未见明确的死亡率差异(RR 0.98,95%CI 0.83-1.16)。
- 证据置信度:低剂量为中等,高剂量为低,剂量间比较为低。
核心结论
- 与安慰剂或常规治疗相比,低剂量(中等置信度)和高剂量(低置信度)糖皮质激素均与较低的短期全因死亡率相关。
- 高剂量与低剂量的间接比较未见明确的死亡率差异,该比较的置信度低。
- 未来需开展大型头对头随机对照试验,评估特定炎症表型患者是否能从高剂量激素中获益。
研究设计与样本
- 系统评价与频率学网络荟萃分析,检索PubMed、Embase和Cochrane数据库截至2026年1月25日的随机对照试验。
- 共纳入32项随机对照试验、9746例参与者;干预按方案规定的地塞米松等效剂量分为高剂量(≥7.5 mg/d)与低剂量(<7.5 mg/d)。
- 主要结局为短期全因死亡率;采用CINeMA框架评估网络荟萃分析估计值的置信度。
主要发现
- 与安慰剂或常规治疗相比,高剂量激素与较低的短期死亡率相关(RR 0.83;95%CI 0.74-0.92)。
- 与安慰剂或常规治疗相比,低剂量激素亦与较低的短期死亡率相关(RR 0.84;95%CI 0.75-0.95)。
- 高剂量与低剂量的间接比较未见明确差异(RR 0.98;95%CI 0.83-1.16)。
- 在重症CAP患者中,高剂量与低剂量的间接估计为RR 1.01(95%CI 0.77-1.33)。
- 多数次要的活性剂量比较结果不精确,未见任一策略的一致优势。
关键数值与推荐
- 高剂量定义为地塞米松等效剂量≥7.5 mg/d,低剂量定义为<7.5 mg/d。
- 主要结局短期全因死亡率:高剂量 vs 安慰剂或常规治疗 RR 0.83(95%CI 0.74-0.92)。
- 主要结局短期全因死亡率:低剂量 vs 安慰剂或常规治疗 RR 0.84(95%CI 0.75-0.95)。
- 高剂量 vs 低剂量间接比较 RR 0.98(95%CI 0.83-1.16);重症CAP患者间接估计 RR 1.01(95%CI 0.77-1.33)。
临床怎么用
- 对CAP住院患者使用辅助糖皮质激素时,现有证据支持低剂量与高剂量均可降低短期死亡率,但两者之间未见明确的剂量优势。
- 不应仅以加大剂量为目标;剂量选择需结合患者炎症表型与个体情况,高剂量证据置信度低。
局限性
- 高剂量与低剂量比较的证据置信度低,多数次要活性剂量比较结果不精确。
- 原文未报告各剂量组的具体不良事件数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Crit Care. 2026 Jul 5;30(1):494. doi: 10.1186/s13054-026-06185-5. ABSTRACT BACKGROUND: Adjunctive corticosteroids improve outcomes in hospitalized patients with community-acquired pneumonia (CAP), but whether higher-dose regimens provide additional benefit over lower-dose regimens remains uncertain. METHODS: We searched PubMed, Embase, and Cochrane databases for randomized controlled trials (RCTs) up to January 25, 2026. Interventions were standardized to protocol-assigned dexamethasone-equivalent doses: high (≥ 7.5 mg/d) and low (< 7.5 mg/d). A frequentist network meta-analysis was performed. The primary outcome was short-term all-cause mortality. Confidence in network meta-analysis estimates was assessed using the Confidence in Network Meta-Analysis (CINeMA) framework. RESULTS: 32 RCTs involving 9,746 participants were included. Compared with placebo or usual care, higher-dose corticosteroids were associated with lower short-term mortality (Risk Ratio [RR], 0.83; 95% Confidence Interval [CI], 0.74-0.92), as were lower-dose corticosteroids (RR, 0.84; 95% CI, 0.75-0.95). The indirect comparison showed no clear difference between higher- and lower-dose regimens (RR, 0.98; 95% CI, 0.83-1.16). In severe patients with CAP, the corresponding indirect estimate was RR 1.01 (95% CI, 0.77-1.33). Most secondary active-dose comparisons were imprecise and showed no consistent advantage of either strategy. CONCLUSION: Compared with placebo or usual care, lower-dose corticosteroids (moderate confidence) and higher-dose corticosteroids (low confidence) were both associated with lower short-term mortality. The indirect higher-versus-lower dose comparison showed no clear mortality difference between dose categories; confidence in this comparison was low. Future research should prioritize large, head-to-head RCTs designed to evaluate whether selected inflammatory phenotypes benefit from higher-dose corticosteroids. PMID: 42402602 | PMC: PMC13613698 | DOI: 10.1186/s13054-026-06185-5
引用
- PubMed 高证据 · 肺炎:Efficacy of higher-dose versus lower-dose corticosteroids in community-acquired pneumonia: a systematic review and network meta-analysis
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。